sur NanoViricides, Inc. (NASDAQ:NNVC)
Innovative Antiviral Technology Discussed in Recent NanoViricides Podcast
NanoViricides, Inc., a prominent player in antiviral nanomedicines, recently highlighted their groundbreaking drug candidate NV-387 in an interview featuring Dr. Anil R. Diwan. Broadcasted by the PODD Conference podcast, Dr. Diwan detailed the potential of NV-387 to transform viral infection treatments. The drug's resilience against viral mutations was emphasized, alongside multiple Phase II clinical trials being pursued thanks to its broad-spectrum efficacy.
The nanoviricide platform offers significant potential beyond virology. It facilitates oral drug delivery and shields active pharmaceutical ingredients (API) from metabolic degradation. Furthermore, the technology allows targeting of specific pathogens, potentially reducing side effects and enhancing effectiveness. This capability might rescue drug candidates sidelined by pharmacokinetic challenges, opening doors to more successful pharmaceutical applications.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.